top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 1 day ago
  • 1 min read

19/03/2026














GSK announced FDA approval of linerixibat for adult patients with PBC (Ref)


GSK announced that the US FDA had approved Lynavoy (linerixibat; an IBAT inhibitor) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC)


  • The approval was based on data from the global Phase 3, GLISTEN/ NCT04950127 trial


    • The trial met both primary and key secondary endpoints, demonstrating significant, rapid (at week two) and sustained (over 24 weeks) improvements in cholestatic pruritus and itch-related sleep interference versus placebo




bottom of page